# Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

> **NCT02752191** · PHASE4 · COMPLETED · sponsor: **Paul Finn** · enrollment: 17 (actual)

## Conditions studied

- Pediatric Congenital Heart Disease

## Interventions

- **DRUG:** ferumoxytol
- **DRUG:** gadofosveset

## Key facts

- **NCT ID:** NCT02752191
- **Lead sponsor:** Paul Finn
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752191, "Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02752191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*